BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. More Details
Flawless balance sheet with limited growth.
Share Price & News
How has BioCardia's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BCDA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: BCDA's weekly volatility has decreased from 15% to 9% over the past year.
7 Day Return
1 Year Return
Return vs Industry: BCDA exceeded the US Biotechs industry which returned 23.1% over the past year.
Return vs Market: BCDA exceeded the US Market which returned 39.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is BioCardia's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StShareholders May Not Be So Generous With BioCardia, Inc.'s (NASDAQ:BCDA) CEO Compensation And Here's Why
4 weeks ago | Simply Wall StIs BioCardia (NASDAQ:BCDA) In A Good Position To Deliver On Growth Plans?
2 months ago | Simply Wall StBioCardia, Inc. (NASDAQ:BCDA) Insiders Increased Their Holdings
Is BioCardia undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate BCDA's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate BCDA's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: BCDA is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: BCDA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BCDA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BCDA is overvalued based on its PB Ratio (4.4x) compared to the US Biotechs industry average (3.4x).
How is BioCardia forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BCDA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BCDA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BCDA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BCDA's revenue (81.6% per year) is forecast to grow faster than the US market (9.4% per year).
High Growth Revenue: BCDA's revenue (81.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BCDA's Return on Equity is forecast to be high in 3 years time
How has BioCardia performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BCDA is currently unprofitable.
Growing Profit Margin: BCDA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BCDA is unprofitable, and losses have increased over the past 5 years at a rate of 12.5% per year.
Accelerating Growth: Unable to compare BCDA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BCDA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.7%).
Return on Equity
High ROE: BCDA has a negative Return on Equity (-72.08%), as it is currently unprofitable.
How is BioCardia's financial position?
Financial Position Analysis
Short Term Liabilities: BCDA's short term assets ($22.7M) exceed its short term liabilities ($4.7M).
Long Term Liabilities: BCDA has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: BCDA is debt free.
Reducing Debt: BCDA currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BCDA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: BCDA has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 12.8% each year.
What is BioCardia current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BCDA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BCDA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BCDA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BCDA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BCDA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Peter Altman (53 yo)
Dr. Peter A. Altman, Ph.D. has been Chief Executive Officer and President of BioCardia, Inc. since 2002. Dr. Altman served as an acting Chief Executive Officer of Lumen Therapeutics from 2004 to 2005. He s...
CEO Compensation Analysis
Compensation vs Market: Peter's total compensation ($USD882.85K) is above average for companies of similar size in the US market ($USD528.84K).
Compensation vs Earnings: Peter's compensation has increased whilst the company is unprofitable.
Experienced Management: BCDA's management team is considered experienced (3.6 years average tenure).
Experienced Board: BCDA's board of directors are considered experienced (4.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 143.1%.
BioCardia, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: BioCardia, Inc.
- Ticker: BCDA
- Exchange: NasdaqCM
- Founded: NaN
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$82.285m
- Shares outstanding: 16.79m
- Website: https://www.biocardia.com
Number of Employees
- BioCardia, Inc.
- 125 Shoreway Road
- Suite B
- San Carlos
- United States
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of h...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/19 02:44|
|End of Day Share Price||2021/06/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.